Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2015-06-11Clinical Trial Update: Abdominal CT to Predict the Risk of Acute Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation [EARLY_Phase 1]
An early-phase study update reporting completion of a trial using abdominal CT to predict acute graft-versus-host disease risk after allogen…
-
CLINICAL_TRIALS trial_result · 2015-06-11Clinical Trial Update: Rituximab and Cyclophosphamide in Treating Patients With High Risk, Refractory, or Relapsed Multiple Myeloma [Phase 2]
Phase 2 clinical trial evaluating the combination of rituximab and cyclophosphamide in patients with high-risk, refractory, or relapsed mult…
-
CLINICAL_TRIALS trial_result · 2015-06-10Clinical Trial Update: Liposomal Doxorubicin, Vincristine, & Dexamethasone Plus Arsenic Trioxide in Untreated Symptomatic Multiple Myeloma [Phase 2]
A Phase 2 clinical trial evaluating a combination of liposomal doxorubicin, vincristine, and dexamethasone plus arsenic trioxide in untreate…
-
CLINICAL_TRIALS trial_result · 2015-06-10Clinical Trial Update: The Effects of Huang-Lian-Jie-Du-Tang（HLJDT) on the Survival of Patients With Multiple Myeloma in Maintain Therapy [Phase 1]
A Phase 1 trial assessing the safety and potential impact of Huang-Lian-Jie-Du-Tang on survival in maintenance therapy for patients with mul…
-
CLINICAL_TRIALS trial_result · 2015-06-09Clinical Trial Update: Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma [Phase 2]
A Phase 2 trial update on using celecoxib to prevent progression to multiple myeloma in patients with MGUS or smoldering myeloma; the study …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2015-06-09Clinical Trial Update: Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance [Phase 2]
A Phase 2 maintenance trial for relapsed multiple myeloma using cyclophosphamide and bortezomib has completed. Sponsored by University Medic…
-
CLINICAL_TRIALS trial_result · 2015-06-08Clinical Trial Update: Phase I Study of OPB-51602 in Patients With Hematologic Malignancies [Phase 1]
Phase I trial results are reported for OPB-51602 in patients with hematologic malignancies including multiple myeloma, non-Hodgkin lymphoma,…
-
CLINICAL_TRIALS withdrawal · 2015-06-08Clinical Trial Update: Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment [Phase 1]
Phase 1 trial evaluating total marrow and total lymph node irradiation with fludarabine and melphalan followed by donor stem cell transplant…
-
CLINICAL_TRIALS trial_result · 2015-06-04Clinical Trial Update: Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related Pain [Phase 1]
Phase 1 trial evaluating oral bicarbonate as an adjuvant for pain reduction in patients with tumor-related pain was terminated.
-
CLINICAL_TRIALS trial_result · 2015-06-03Clinical Trial Update: Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple Myeloma [Phase 1]
Phase 1b multicenter trial evaluating carfilzomib in combination with lenalidomide and dexamethasone for relapsed multiple myeloma has compl…
-
CLINICAL_TRIALS trial_result · 2015-06-01Clinical Trial Update: Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating chloroquine with VELCADE and cyclophosphamide in relapsed/refractory multiple myeloma; study terminated with posted…
-
CLINICAL_TRIALS withdrawal · 2015-05-29Clinical Trial Update: Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers
A clinical trial evaluating perceived burden in late-stage cancer patients and their caregivers has been withdrawn.
-
CLINICAL_TRIALS trial_result · 2015-05-25Clinical Trial Update: Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma [Phase 3]
Phase 3 trial evaluating DOXIL (pegylated liposomal doxorubicin) in combination with Velcade versus Velcade monotherapy for relapsed multipl…
-
CLINICAL_TRIALS trial_result · 2015-05-15Clinical Trial Update: A Phase II Trial of Anti-KIR in Smoldering Multiple Myeloma [Phase 2]
Phase II trial of Anti-KIR in smoldering multiple myeloma was terminated; results posted in 2015.
-
CLINICAL_TRIALS trial_result · 2015-05-13Clinical Trial Update: Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma [Phase 1, Phase 2]
This document reports dose-finding results for lenalidomide used as maintenance therapy in patients with multiple myeloma in a Phase 1/2 tri…
-
FDA approval · 2015-04-24FDA Approved: KYPROLIS — Supplemental Application (Onyx Pharmaceuticals, Inc.)
FDA approved a supplemental application for KYPROLIS (carfilzomib) submitted by Onyx Pharmaceuticals, Inc.
-
CLINICAL_TRIALS withdrawal · 2015-04-24Clinical Trial Update: Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma [Phase 2]
Phase 2 trial of bortezomib, dexamethasone, and cyclophosphamide for older patients with multiple myeloma has been withdrawn.
-
FDA approval · 2015-04-23FDA Approved: POMALYST — Supplemental Application (Celgene Corporation)
The FDA approved a supplemental application for POMALYST (pomalidomide) by Celgene Corporation, resulting in changes to the drug's labeling.
-
CLINICAL_TRIALS trial_result · 2015-04-20Clinical Trial Update: Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) [Phase 1]
Phase 1 update on weekly dosing of SCH 727965 in patients with advanced cancer, including solid tumors, non-Hodgkin lymphoma, multiple myelo…
-
CLINICAL_TRIALS trial_result · 2015-04-16Clinical Trial Update: ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.
This observational study assesses the safety and effectiveness of bortezomib at first relapse after participation in HOVON-49/50 first-line …
-
CLINICAL_TRIALS trial_result · 2015-04-15Clinical Trial Update: Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma [Phase 1]
Phase 1 clinical trial of a viral therapy for relapsed or refractory multiple myeloma has completed enrollment. The trial also included pati…
-
CLINICAL_TRIALS withdrawal · 2015-04-14Clinical Trial Update: Open-label Study, to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Bone Lesions Secondary to Multiple Myeloma. [Phase 4]
This clinical trial update states that a Phase 4 open-label study of zoledronic acid in patients with bone lesions due to multiple myeloma h…
-
FDA approval · 2015-04-09FDA Approved: ZOLEDRONIC ACID — Supplemental Application (Dr.Reddy's Laboratories Ltd)
FDA approved a supplemental application for zoledronic acid from Dr. Reddy's Laboratories Ltd (ANDA 091363), granting regulatory approval of…
-
CLINICAL_TRIALS trial_result · 2015-04-06Clinical Trial Update: Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma [Phase 2]
A Phase II study evaluating the bone-related effects of bortezomib in relapsed or refractory multiple myeloma; the trial was terminated with…
-
CLINICAL_TRIALS withdrawal · 2015-04-06Clinical Trial Update: A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib [Phase 2]
Phase 2 study evaluating bortezomib in combination with pegylated liposomal doxorubicin for relapsed multiple myeloma has been withdrawn.